Report Contents

  1. Coriell Personalized Medicine Collaborative Research Study Report. This report includes all data included in the clinical report as well as supplemental drug specific interpretations and educational material.
  2. Clinical Report. This report was generated and approved by Coriell’s CLIA certified genotyping laboratory.
Coriell Institute for Medical Research
Coriell Genotyping and Microarray Center
403 Haddon Avenue Camden, NJ 08103
Phone: 856-966-7377 Fax: 856-964-0254  www.coriell.org
CYP2C19 GENE TEST FOR VORICONAZOLE RESPONSE
Name: NATALIE DEMO
Date of Birth:
Coriell ID: DEMONAT
Lab Accessioning Number: DEMONAT
Ordering Physician:
Sample Type: Saliva
Gender: Female
Date Collected:
Date Received:
Date of Report: 01/11/2017
NAME OF GENE: CYP2C19 LOCATION OF GENE: 10q24
Variants tested RESULT Reference Genotype
rs4244285 (CYP2C19*2) GG G G
rs4986893 (CYP2C19*3) GG G G
rs28399504 (CYP2C19*4) GG A A
rs56337013 (CYP2C19*5) CC C C
rs72558184 (CYP2C19*6) GG G G
rs72558186 (CYP2C19*7) TT T T
rs41291556 (CYP2C19*8) TT T T
rs17884712 (CYP2C19*9) GG G G
rs6413438 (CYP2C19*10) CC C C
rs12248560 (CYP2C19*17) CC C C
^ When the Result for all CYP2C19 variants tested are the same as the reference, the Combined Result is called CYP2C19 *1/*1. In some cases, due to technical limitations, your Combined Result may not be able to be determined. It may still be possible to provide an interpretation for such a result based on possible genetic outcomes (for example in rare combinations of non-reference results at more than one variant, or the presence of a “result not available” at one or more variants).
Risk interpretation based on Coriell’s CYP2C19/Voriconazole Response Genotype Translation Version 1 (January 2017).

Interpretation

This individual is expected to be a Voriconazole Poor Metabolizer based on the Combined Genetic Result: CYP2C19*4/*4

Individuals who are poor metabolizers eliminate voriconazole more slowly and may be at increased risk for adverse reactions when taking a standard dose of voriconazole.

Test Limitations

DNA-based testing is highly accurate, however there are many sources of potential error including: mis-identification of samples, rare technical errors, trace contamination of PCR reactions, and rare genetic variants that interfere with analysis. There may be other variants in the CYP2C19 gene that are not included in this test, that influence the response to voriconazole. This test or one or more of its components was developed and its performance characteristics determined by the Coriell Institute for Medical Research. It has not been approved by the Food and Drug Administration (FDA). The FDA has determined that such approval is not necessary. The Coriell Institute is regulated under the Clinical Laboratory Improvement Amendments (CLIA) of 1988 as qualified to perform high-complexity testing.

Test Methodology

Saliva samples were collected using Oragene DNA Collection Kits (DNA Genotek) and DNA was extracted manually according to the manufacturer’s instructions or automatically using a DNAdvance Kit (Agencourt). Purified DNA was quantified using UV absorbance at 260 nm. One microgram of the resulting DNA from each sample was used as template in the Affymetrix DMET Plus GeneChip assay. Data analysis was performed using Affymetrix DMET Console software.

electronically signed by
Owatha L. Tatum, PhD, Laboratory Director


References

  1. Ikeda Y, et al. Clin Pharmacol Ther. 2004 Jun;75(6):587-8.
  2. Karlsson MO, et al. Antimicrob Agents Chemother. 2009 Mar;53(3):935-44.
  3. Lei, HP, et al. Ann Pharmacother 43(4): 726-731.
  4. Levin, MD, et al. J Antimicrob Chemother 60(5): 1104-1107.
  5. Matsumoto K, et al. Int J Antimicrob Agents. 2009 Jul;34(1):91-4.
  6. Mikus G, et al. Clin Pharmacol Ther. 2006 Aug;80(2):126-35.
  7. Rengelshausen, JM, et al. Clin Pharmacol Ther 78(1): 25-33.
  8. Wang G, et al. Eur J Clin Pharmacol. 2009 Mar;65(3):281-5.
  9. Weiss J, et al. J Clin Pharmacol. 2009 Feb;49(2):196-204.